<DOC>
	<DOC>NCT01455142</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of the trial is to test for bioequivalence between two formulations of insulin degludec/insulin aspart (IDegAsp) to see if the efficacy and safety obtained with formulation 1 can be assumed identical for formulation 2.</brief_summary>
	<brief_title>A Trial to Test for Bioequivalence Between NN1045 and NN5401 in Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Type 1 diabetes mellitus (as diagnosed clinically) for 12 months or longer Body mass index from 18.0 to 28.0 kg/m^2 (both inclusive) HbA1c below or equal to 9.5% by central laboratory analysis Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day) Not able or willing to refrain from smoking and use of nicotine gum or transdermal nicotine patches during the inpatient period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>